Nina Bhardwaj Selected Research

poly ICLC

1/2020	Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
1/2019	Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial.
10/2018	Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial.
8/2014	Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nina Bhardwaj Research Topics

Disease

97	Neoplasms (Cancer) 05/2022 - 03/2003
36	Melanoma (Melanoma, Malignant) 01/2022 - 07/2005
24	Infections 07/2022 - 01/2002
7	HIV Infections (HIV Infection) 01/2019 - 03/2011
6	Inflammation (Inflammations) 05/2022 - 05/2014
6	Testicular Neoplasms (Testicular Cancer) 01/2018 - 07/2005
5	Urinary Bladder Neoplasms (Bladder Cancer) 01/2022 - 08/2014
4	COVID-19 03/2022 - 01/2020
4	Virus Diseases (Viral Diseases) 01/2016 - 01/2005
4	Neoplasm Metastasis (Metastasis) 10/2014 - 02/2009
3	Multiple Myeloma 01/2020 - 07/2005
3	Human Influenza (Influenza) 04/2016 - 06/2013
3	Persistent Infection 06/2007 - 10/2004
2	Lung Neoplasms (Lung Cancer) 01/2022 - 01/2020
2	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 01/2021
2	Fatigue 01/2022 - 10/2018
2	Carcinogenesis 01/2021 - 05/2007
2	Hereditary Nonpolyposis Colorectal Neoplasms (Hereditary Nonpolyposis Colorectal Cancer) 01/2021 - 12/2020
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2020 - 08/2014
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2018 - 10/2013
2	Breast Neoplasms (Breast Cancer) 10/2014 - 12/2012
1	Porcine Reproductive and Respiratory Syndrome (PRRS) 07/2022
1	RNA Virus Infections 07/2022
1	Necrosis 01/2022
1	Constipation 01/2022
1	Polycythemia Vera 12/2021
1	Essential Thrombocythemia 12/2021
1	Primary Myelofibrosis (Myelosclerosis) 12/2021
1	Merkel Cell Carcinoma 12/2021
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2021

Drug/Important Bio-Agent (IBA)

32	AntigensIBA 01/2021 - 04/2003
29	VaccinesIBA 03/2022 - 01/2003
19	Proteins (Proteins, Gene)FDA Link 01/2020 - 07/2005
16	CytokinesIBA 05/2022 - 07/2005
13	RNA (Ribonucleic Acid)IBA 01/2021 - 07/2005
11	Immune Checkpoint InhibitorsIBA 01/2022 - 10/2013
10	Peptides (Polypeptides)IBA 01/2022 - 01/2005
9	Cancer VaccinesIBA 01/2022 - 01/2009
6	EpitopesIBA 01/2021 - 12/2004
6	Biomarkers (Surrogate Marker)IBA 01/2021 - 08/2014
6	Neoplasm Antigens (Tumor Antigens)IBA 03/2017 - 01/2009
5	LigandsIBA 07/2022 - 07/2013
5	Matrix Metalloproteinase 2 (Gelatinase A)IBA 01/2021 - 03/2011
4	Antiviral Agents (Antivirals)IBA 07/2022 - 05/2007
4	poly ICLCIBA 01/2020 - 08/2014
4	Monatide (IMS 3015)IBA 01/2020 - 05/2007
4	Imiquimod (Aldara)FDA LinkGeneric 10/2014 - 07/2008
4	MART-1 AntigenIBA 08/2011 - 08/2008
3	AntibodiesIBA 01/2022 - 08/2011
3	ChemokinesIBA 01/2021 - 05/2003
3	Biological ProductsIBA 12/2020 - 01/2017
3	IpilimumabIBA 01/2018 - 08/2011
3	Monophenol Monooxygenase (Tyrosinase)IBA 03/2015 - 08/2008
3	Monoclonal AntibodiesIBA 03/2015 - 10/2013
3	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2015 - 08/2011
2	Pattern Recognition ReceptorsIBA 07/2022 - 12/2015
2	MucinsIBA 01/2022 - 05/2014
2	CalreticulinIBA 01/2022 - 01/2019
2	Immunoglobulins (Immunoglobulin)IBA 01/2022 - 05/2014
2	CTLA-4 AntigenIBA 01/2022 - 10/2013
2	cyclopropapyrroloindoleIBA 01/2021 - 11/2019
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2020 - 02/2009
2	Protein Subunit VaccinesIBA 01/2020 - 01/2017
2	Interleukin-10 (Interleukin 10)IBA 01/2019 - 07/2011
2	Poly I-CIBA 10/2018 - 04/2016
2	Interleukin-5 (Interleukin 5)IBA 01/2018 - 11/2008
2	tremelimumabIBA 01/2018 - 01/2017
2	InflammasomesIBA 01/2016 - 05/2014
2	InterleukinsIBA 01/2015 - 05/2014
2	Vaccine AdjuvantsIBA 01/2015 - 07/2008
2	Interferon Type IIBA 02/2014 - 12/2008
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 10/2013 - 04/2013
2	AIDS VaccinesIBA 06/2013 - 04/2013
2	MicroRNAs (MicroRNA)IBA 07/2011 - 02/2009
2	Messenger RNA (mRNA)IBA 11/2008 - 07/2005
1	RNA Polymerase IIIIBA 07/2022
1	Interleukin-6 (Interleukin 6)IBA 05/2022
1	Conditioned Culture MediaIBA 05/2022
1	Tyrosine (L-Tyrosine)FDA Link 01/2022
1	Transforming Growth Factor-beta Type II ReceptorIBA 01/2022
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022
1	SteroidsIBA 01/2022
1	Pharmaceutical PreparationsIBA 01/2022
1	Creatine Kinase (Creatine Phosphokinase)IBA 01/2022
1	COVID-19 VaccinesIBA 01/2022
1	cemiplimabIBA 01/2022
1	pembrolizumabIBA 12/2021
1	ruxolitinibIBA 12/2021
1	HLA-DR Antigens (HLA-DR)IBA 12/2021
1	ManganeseIBA 01/2021
1	PLX5622IBA 01/2021
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021
1	Small Cytoplasmic RNAIBA 01/2021
1	Macrophage Colony-Stimulating FactorIBA 01/2021

Therapy/Procedure

44	Immunotherapy 01/2022 - 01/2003
28	Therapeutics 01/2022 - 01/2002
3	Drug Therapy (Chemotherapy) 01/2018 - 07/2011
2	Duration of Therapy 01/2022 - 01/2018
2	Injections 04/2016 - 08/2014
1	Prostatectomy (Retropubic Prostatectomy) 05/2022